Filing Flows › Caris Life Sciences (CAI) › Capital expenditures
Caris Life Sciences (CAI) capital expenditures by quarter
Caris Life Sciences' capital expenditures were $22.1M in Q2 2026 (second quarter 2026), +113% from Q1 2026. Over the last 5 quarters it ranged from $1.4M (Q2 2025) to $22.1M (Q2 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $22.1M | +113% | 16× |
| Q1 2026 | $10.3M | +103% | — |
| Q4 2025 | $5.1M | -28% | — |
| Q3 2025 | $7.1M | +412% | — |
| Q2 2025 | $1.4M | — | — |
Q2 2026 at a glance
Caris Life Sciences, Q2 2026: revenue $264M (+45% year over year), operating margin 10.2%, net loss $637K, operating cash flow $28.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Caris Life Sciences' capital expenditures?
Caris Life Sciences' capital expenditures were $22.1M in Q2 2026 (second quarter 2026), +113% from Q1 2026.
How has Caris Life Sciences' capital expenditures changed?
Over the last 5 quarters it ranged from $1.4M (Q2 2025) to $22.1M (Q2 2026).